earnings
PC
NASDAQ · PCSA
Processa Pharmaceuticals, Inc.
Healthcare · Biotechnology
$1.61
Down-$0.12 (-7.45%)
Updated Oct 5, 2026, 11:16 PM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 15.65M
- P/E ratio
- -1.01
- Dividend yield
- 0.00%
- 52-week range
- $1.57 – $3.45
- Volume
- 15.11K
- Avg. volume
- 9.87M
Price performance · PCSA
PCSA price history
1M range · 19 trading sessions · Daily adjusted prices
Prices through Oct 2, 2026
PCSA closed at $1.61 after 19 trading sessions, down 25.46% for the selected period.
- Last close
- $1.61
- Period change
- -25.46%
- Period low
- $1.61
- Period high
- $2.16
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 2, 2026 | $1.73 | $1.7395 | $1.60 | $1.61 | 15.11K |
| Oct 1, 2026 | $1.59 | $1.6449 | $1.5701 | $1.62 | 10.18K |
| Sep 30, 2026 | $1.83 | $1.848 | $1.57 | $1.64 | 84.17K |
| Sep 29, 2026 | $1.76 | $1.8295 | $1.75 | $1.76 | 9.25K |
| Sep 28, 2026 | $1.84 | $1.84 | $1.77 | $1.84 | 9.4K |
| Sep 25, 2026 | $1.88 | $1.93 | $1.80 | $1.84 | 8.54K |
| Sep 24, 2026 | $1.89 | $1.9391 | $1.80 | $1.85 | 5.15K |
| Sep 23, 2026 | $1.90 | $1.9699 | $1.865 | $1.89 | 4.74K |
| Sep 22, 2026 | $1.91 | $2.02 | $1.85 | $1.88 | 74.52K |
| Sep 21, 2026 | $1.87 | $1.9437 | $1.84 | $1.84 | 16.47K |
| Sep 18, 2026 | $1.92 | $1.96 | $1.84 | $1.96 | 6.41K |
| Sep 17, 2026 | $1.85 | $1.99 | $1.85 | $1.90 | 21.77K |
| Sep 16, 2026 | $1.93 | $1.95 | $1.85 | $1.85 | 17.09K |
| Sep 15, 2026 | $1.95 | $1.96 | $1.88 | $1.9567 | 15.69K |
| Sep 14, 2026 | $1.97 | $2.11 | $1.87 | $1.88 | 26.8K |
| Sep 11, 2026 | $1.90 | $2.12 | $1.90 | $2.08 | 39.35K |
| Sep 10, 2026 | $1.99 | $2.03 | $1.82 | $1.85 | 102.28K |
| Sep 9, 2026 | $2.08 | $2.11 | $1.98 | $1.99 | 25.47K |
| Sep 8, 2026 | $2.15 | $2.165 | $2.05 | $2.16 | 35.84K |
Latest PCSA news
The latest Smart Investors Daily articles mentioning PCSA.
Stock researchResearch & News · Analysis
Company
Market Activity
Research & News
Loading stock research…

